The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Angela L. Talton named first chief diversity, equity and inclusion officer at City of Hope

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Angela L. Talton was named senior vice president and chief diversity, equity and inclusion officer at City of Hope.

Talton will begin the role Jan. 11. Her expertise in diversity, equity and inclusion encompasses leadership development, recruitment and retention of talent, communication strategy, philanthropic giving, supplier diversity and analytics.

Most recently, Talton successfully advised national clients through her firm, ALTalton Consulting. Prior to that, she served in senior executive roles at Nielson for nearly 12 years, including chief diversity officer, senior vice president of global diversity and inclusion, and senior vice president of global call center operations.

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

How will FDA regulate psychedelics?

FDA has been taking a look at psychedelics as a potential treatment for psychiatric and substance abuse disorders, recently publishing a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA. 
Guest Editorial

Cancer progress is not reaching everyone. Native Nations must be part of the solution.

In 1971, the National Cancer Act set the United States on a path to confront one of its most formidable public health challenges. More than five decades later, the progress is undeniable. The latest 2026 report from the American Cancer Society shows continued declines in overall cancer mortality and improvements in survival for many major cancer types. Recent advances in early detection, prevention, and treatment are saving lives.
By Rodney Haring
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account